SUMMARY
Continuing its robust start to the new financial year, the Fund generated a 2.6% return during a volatile August. By way of comparison, the RBA cash rate plus 6% returned approximately 0.7%, while the All Ordinaries Accumulation Index returned 3.2%.
The Fund continues to outperform its benchmark since inception just over 17 years ago, with a return of 9.1% per annum versus its RBA equity risk premium adjusted benchmark of 8.6% and the market return of 7.6% for the same period.
We remain focused on our objective of capital preservation while generating a fair return for equity risk. It is worth noting that cash levels in the Fund increased to 12% following material profit taking during a bifurcated earnings reporting season.







COMMENTARY
The majority of Australian listed companies reported their FY25 results during August. It is an intense period for investors as company management releases their financial statements, followed by fronting up to presentations, group and one on one meetings. It’s a deluge of new information during a concentrated period – often compared to “drinking from a fire hose” – for the investment community as they assess the implications for their portfolios.
Many market participants have adopted a “shoot first, ask questions later” approach, choosing to focus on the all important “Beat/Miss versus Consensus” on both historic earnings and forward looking guidance metrics. The August 2025 earnings season was particularly volatile, with share price reactions of 20% or greater on the release day becoming commonplace.
The Fund was not immune to this activity. However, our long tail of winners outweighed the few losers. On the negative side, we were disappointed by the veracity of CSL and James Hardie management assertions regarding the underlying performance of their core businesses. In particular, CSL’s usually dominant blood fractionalisation business proved remarkably vulnerable to competitive forces. Similarly, the inexplicably sharp drop off in demand by home builders at James Hardie appeared to catch management by surprise and remains difficult to understand. Our holdings in Amcor and Ramsay also underperformed.
Fortunately, our long tail of positive results more than compensated for the above issues. Evolution Mining, Stockland, NAB, Super Group, Westpac, BHP, Metcash, and Ampol were our larger positive contributors. Expectations that lower interest rates will drive credit growth, consumer discretionary spending and residential house prices appear to be impacting the outlook for quality players in these areas.
Another feature of the month was the trimming activity. The Fund used result-day share price bounces to crystallise gains from what we viewed as overly enthusiastic investor reactions. Positions in ResMed, Stockland, NAB, Medibank and Evolution Mining were reduced. These selective sales, together with dividend receipts, lifted cash levels to 12%. This provides us with increased flexibility to deploy capital as new opportunities emerge.
We are particularly cognizant of a heightened level of “twitchiness” amongst market participants. Our view is that market valuations are high with little or no fundamental support when/if company results do not meet expectations. Our focus remains on fundamental valuation rather than momentum based investing.